Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease.

E. Teske

doi:10.1002/ajh.26031

Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease.

CS_Cancer

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	E29-E32
Number of pages	4
Journal	American Journal of Hematology
Volume	96
Issue number	1
DOIs	https://doi.org/10.1002/ajh.26031
Publication status	Published - Jan 2021

Access to Document

10.1002/ajh.26031Licence: CC BY

ajh.26031Final published version, 1.08 MBLicence: CC BY

Cite this

@article{8fc186c4950242368459f67624d98f5b,

title = "Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease.",

author = "E. Teske",

note = "Funding Information: Both M.A.E.R., M.E.H., J.G., E.N., M.H.C., and E.J.v.B. are clinical researchers within the Sickle Cell Outcome Research (SCORE) consortium, a multicenter clinical research collaboration in the Netherlands, which gave input on the work described in this manuscript for which we value highly. This research has been funded in part by Eurostars grant estar18105 and by an unrestricted grant provided by RR Mechatronics. This work is also funded by K08 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, and by support from the Department of Pediatrics, Baylor College of Medicine. Funding Information: M.A.E.R., J.B., and B.A.vO. received grant funding from RR Mechatronics. R.v.W. received grant funding from Agios Pharmaceuticals Inc and RR Mechatronics. E.J.v.B. received grant funding Agios Pharmaceuticals Inc, RR Mechatronics, Novartis and Pfizer for investigator initiated research projects. V.A.S. received grant funding from Global Blood Therapeutics, Emmaus, and Novartis for investigator initiated research projects. Funding Information: The authors would like to thank all patients that donated blood for this study. The authors also thank the technicians of the Central Diagnostic Laboratory, Specialized Hematology, University Medical Center Utrecht. As well as the clinical research coordinators of the department of pediatric hematology at the Erasmus Medical Center Rotterdam and the department of hematology at the Amsterdam University Medical Centers. Both M.A.E.R., M.E.H., J.G., E.N., M.H.C., and E.J.v.B. are clinical researchers within the Sickle Cell Outcome Research (SCORE) consortium, a multicenter clinical research collaboration in the Netherlands, which gave input on the work described in this manuscript for which we value highly. This research has been funded in part by Eurostars grant estar18105 and by an unrestricted grant provided by RR Mechatronics. This work is also funded by K08 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, and by support from the Department of Pediatrics, Baylor College of Medicine.",

year = "2021",

month = jan,

doi = "10.1002/ajh.26031",

language = "English",

volume = "96",

pages = "E29--E32",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Oxygen gradient ektacytometry-derived biomarkers are associated with vaso-occlusive crises and correlate with treatment response in sickle cell disease.

AU - Teske, E.

N1 - Funding Information: Both M.A.E.R., M.E.H., J.G., E.N., M.H.C., and E.J.v.B. are clinical researchers within the Sickle Cell Outcome Research (SCORE) consortium, a multicenter clinical research collaboration in the Netherlands, which gave input on the work described in this manuscript for which we value highly. This research has been funded in part by Eurostars grant estar18105 and by an unrestricted grant provided by RR Mechatronics. This work is also funded by K08 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, and by support from the Department of Pediatrics, Baylor College of Medicine. Funding Information: M.A.E.R., J.B., and B.A.vO. received grant funding from RR Mechatronics. R.v.W. received grant funding from Agios Pharmaceuticals Inc and RR Mechatronics. E.J.v.B. received grant funding Agios Pharmaceuticals Inc, RR Mechatronics, Novartis and Pfizer for investigator initiated research projects. V.A.S. received grant funding from Global Blood Therapeutics, Emmaus, and Novartis for investigator initiated research projects. Funding Information: The authors would like to thank all patients that donated blood for this study. The authors also thank the technicians of the Central Diagnostic Laboratory, Specialized Hematology, University Medical Center Utrecht. As well as the clinical research coordinators of the department of pediatric hematology at the Erasmus Medical Center Rotterdam and the department of hematology at the Amsterdam University Medical Centers. Both M.A.E.R., M.E.H., J.G., E.N., M.H.C., and E.J.v.B. are clinical researchers within the Sickle Cell Outcome Research (SCORE) consortium, a multicenter clinical research collaboration in the Netherlands, which gave input on the work described in this manuscript for which we value highly. This research has been funded in part by Eurostars grant estar18105 and by an unrestricted grant provided by RR Mechatronics. This work is also funded by K08 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, and by support from the Department of Pediatrics, Baylor College of Medicine.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85096711024&partnerID=8YFLogxK

U2 - 10.1002/ajh.26031

DO - 10.1002/ajh.26031

M3 - Comment/Letter to the editor

C2 - 33095451

SN - 0361-8609

VL - 96

SP - E29-E32

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 1

ER -